JOYCE AWUJOR: Open Payments
NPI 1063119832 · HAVRE DE GRACE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,246 in 83 payments from 16 companies in 2025. Trend: 2023 $577 · 2024 $2,036 · 2025 $2,246
Food & beverage: $2,246
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $357 |
| Otsuka America Pharmaceutical, Inc. | 9 | $260 |
| Neurocrine BioSciences, Inc. | 9 | $253 |
| Janssen Pharmaceuticals, Inc | 7 | $251 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $238 |
| Vanda Pharmaceuticals Inc. | 6 | $178 |
| Axsome Therapeutics, Inc. | 4 | $172 |
| E.R. Squibb & Sons, L.L.C. | 7 | $155 |
| Supernus Pharmaceuticals, Inc. | 5 | $93 |
| Alkermes, Inc. | 4 | $72 |
Products named: VRAYLAR, INVEGA SUSTENNA, INGREZZA, CAPLYTA, REXULTI, Auvelity, COBENFY, Qelbree.
Industry payments across MD — which companies pay providers there.
